This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Coronavirus Scare Supports These Biotech ETFs & Stocks
by Sanghamitra Saha
Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.
Why Biotech ETFs are Surging to New Highs
by Neena Mishra
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
A Guide to Biotech ETF Investing
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.
Biotech Tops in November: Best ETFs & Stocks
by Sweta Killa
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
Why Gold is Headed to Zero -- And What You Should Buy Instead
by Kevin Cook
In 2026, NASA mission Psyche will explore an asteroid that could hold over $5,000 quadrillion in gold
Genomics ETFs Surge on CRISPR's Gene Editing Progress
by Sweta Jaiswal, FRM
The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks
by Sanghamitra Saha
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
S&P 500 at Record High: 6 ETF Winners of Last Week
by Sweta Killa
The S&P 500 hit record highs last week, with the index rising for the fourth consecutive week, marking its longest winning streak since March.
Navigating The Healthcare Industry: Science Fiction Turns to Reality
by Panel Of Zacks Experts
Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!
Tap Revenue Growth With These ETFs & Dump Earnings Recession
by Sanghamitra Saha
These sector ETFs could be played to highlight revenue growth in the third quarter.
ETFs Poised to Benefit from Gene Editing Revolution
by Sweta Jaiswal, FRM
Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
ETFs to Gain From the Booming Genomics Market
by Sweta Jaiswal, FRM
Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.
Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.
5 U.S. ETFs Seeing Fireworks Ahead of July Fourth
by Sweta Killa
These ETFs focus exclusively on U.S. equities and deserve the attention of investors seeking a domestic tilt to their portfolio ahead of the Jul 4 holiday.
5 Sector ETFs That Beat the Market in the First Half
by Sweta Killa
With just a trading session left to end the first half, the Dow Jones is up about 13.7% while the S&P 500 and Nasdaq have gained 16.7% and 20.1%, respectively.
Why These Innovative Biotech ETFs Are Soaring
by Neena Mishra
Strong M&A activity has sent shares of many small, innovative biotech companies surging
S&P 500 Hits New High: 10 Top-Performing ETFs YTD
by Sweta Killa
Braving global growth concerns, the bulls are back with the S&P 500 surging to its first record close since April.
Pfizer-Array Biopharma Deal Bump Up Biotech ETFs
by Sweta Killa
Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.
ETF Winners & Losers As China Retaliates
by Sweta Killa
The renewed trade spat has led to just a few winners but a number of losers from various corners of the investing space.
Forget Earnings Recession: Tap Revenue Growth With These ETFs
by Sanghamitra Saha
First-quarter earnings growth is likely to be negative this year, but revenues will grow. So, play revenue growth with these sector ETFs.
Biotechnology Market on a Tear: 5 ETFs in Spotlight
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
Global X Launches GNOM ETF to Tap Booming Genomics Space
by Sweta Jaiswal, FRM
Having exposure to trending areas like Robotics & AI, e-commerce and IoT, Global X is set to gain from the booming genomics market with the GNOM ETF.
Best Performing ETFs of the First Quarter
by Neena Mishra
Major indexes posted their best quarterly performance since the financial crisis; here are some ETFs that soared during the quarter
ETFs That Topped & Flopped in Q1
by Sweta Killa
We have highlighted both the best and worst performing ETFs of Q1 from different zones or industries.